Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 3/20 | 0.41 |
| ▸ | DRD2 | P14416 | 3/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28546457 | 0.77 | KMT2A (0.43) | KDM4EALDH1A1HPGDPARP1CREBBP | |
| SCHEMBL15746289 | 0.74 | ALDH1A1 (0.43) | KDM4EALDH1A1HPGD | |
| SCHEMBL25509092 | 0.74 | TRPV1 (0.42) | ALDH1A1MTNR1AMTNR1B | |
| SCHEMBL26701316 | 0.73 | HIF1A (0.44) | PARP1MTNR1AMTNR1B | |
| SCHEMBL26701329 | 0.73 | MTNR1A (0.34) | ALDH1A1HPGDPARP1MTNR1AMTNR1B | |
| SCHEMBL8307788 | 0.72 | DRD2 (0.55) | DRD2 | |
| SCHEMBL3396949 | 0.72 | ALDH1A1 (0.47) | KDM4EALDH1A1HPGD | |
| SCHEMBL31359858 | 0.72 | BCL2L1 (0.52) | KDM4EALDH1A1HPGD | |
| SCHEMBL29573534 | 0.72 | ALDH1A1 (0.47) | KDM4EALDH1A1HPGD | |
| SCHEMBL4570298 | 0.72 | BCL2L1 (0.52) | KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10889555-B2 | Sulfonamide compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-01-12 | — | — | US | disclosed |
| US-20200405697-A1 | Antitumor Agent | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-12-31 | — | — | US | disclosed |
| US-20200399235-A1 | Sulfonamide Compound or Salt Thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-12-24 | — | — | US | disclosed |
| US-20200157066-A1 | Sulfonamide Compound or Salt Thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-05-21 | — | — | US | disclosed |
| EP-3466934-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017209155-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | 大鵬薬品工業株式会社 | 2017-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399235-A1 | Sulfonamide Compound or Salt Thereof | RNASEH1, SNRPA1, RRM2 | KDM4E 1551/4885ALDH1A1 1103/4885HPGD 3074/4885 |
| US-20200157066-A1 | Sulfonamide Compound or Salt Thereof | RNASEH1, SNRPA1, RRM2 | KDM4E 1551/4885ALDH1A1 1103/4885HPGD 3074/4885 |
| US-10889555-B2 | Sulfonamide compound or salt thereof | RNASEH1, SNRPA1, RRM2 | KDM4E 1551/4885ALDH1A1 1103/4885HPGD 3074/4885 |
| US-20200405697-A1 | Antitumor Agent | HNRNPR, RRM2, RRM2B | KDM4E 2851/4885ALDH1A1 1397/4885HPGD 2495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.